SLGT-2 inh have cardiovascular and renal protection effect. Elderly diabetic patients are more prone to cardiovascular events but are frailer with more comorbidities and more prone to SLG2-inh adverse effects. These patients are not represented in RCT as they not fulfil inclusion criteria.

Aim: Evaluate long term safety and efficacy of adding SGLT2 inhibitors to Elderly DM2 patients with uncontrolled glycemia in real life experience.

Method: We studied 72 Elderly DM2 patients treated with SGLT2 inhibitors for more than 5 years in our Health Department. Efficacy, Safety and Durability data was collected from our computerized Primary and Hospital Medical Records at baseline and after 5 years.

Results: Patients’ basal data: mean age: 71,6 years, 42% women, mean period diabetes: 12,5 years. Prevalence Hypertension 79%, Dyslipidemia 81% Obesity 51% and previous cardiovascular events 42%. Antidiabetic Treatment: Metformin (78%), SU (31%) Gliptines (37%) Pioglitazone (12%), GLP-1A (13%) and Insulin (36%). Results Before and After 5-year SGLT2 inh Treatment: HbA1c. 8,5 vs. 7,2% (p < 0,05); (38% maintained HbA1c < 7.5%) Weight: 90.9 vs. 86.7 kg (p< 0,05); Systolic BP: 133.2 vs. 128.6 mmHg (P< 0,05) Albumin-Creatinine ratio (ACR): 58,7 vs. 36,2 mg/g (p< 0,05) There were no statistical significant changes in e-GFR, microalbuminuria, lipid profile and hematocrit. No falls, volume depletion, severe hypoglycemia or ketoacidosis were recorded. 17% were treated for urinary-genital infections and half of them withdraw SLGT2i. 22% had a new non-fatal cardiovascular events and 6% heart failure hospitalization. There was a 17% mortality mainly due to neoplasic causes.

Discussion: 5-year SGLT2 inh. treatment in Elderly DM2 patients was safe and effective as in RCT. They had a significant maintained reduction in HbA1c, weight, systolic BP and ACR. Genito-urinary infection, although not frequent, was the main cause of withdraw.

Disclosure

C. Trescoli: None. P. Palasi: None. P. Platero: None. A. Trescoli-Garcia: None. B. Espinosa: None. M. Vercher: None.

© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.